Probable transmission of hepatitis E virus (HEV) via transfusion in the United States.
Journal
Transfusion
ISSN: 1537-2995
Titre abrégé: Transfusion
Pays: United States
ID NLM: 0417360
Informations de publication
Date de publication:
03 2019
03 2019
Historique:
received:
01
01
2018
revised:
30
09
2018
accepted:
02
10
2018
pubmed:
1
2
2019
medline:
9
11
2019
entrez:
1
2
2019
Statut:
ppublish
Résumé
Hepatitis E virus (HEV) can inapparently infect blood donors. To assess transfusion transmission of HEV in the United States, which has not been documented, a donor-recipient repository was evaluated. To identify donations that contained HEV RNA and were linked to patient-recipients with antibody evidence of HEV exposure, we assayed samples from the Retrovirus Epidemiology Donor Study (REDS) Allogeneic Donor and Recipient repository that represents 13,201 linked donations and 3384 transfused patients. Posttransfusion samples, determined to contain IgG anti-HEV by enzyme-linked immunosorbent assay, were reassayed along with corresponding pretransfusion samples for seroconversion (incident exposure) or at least fourfold IgG anti-HEV increase (reexposure). HEV-exposed patients were linked to donations in which HEV RNA was then detected by reverse-transcription quantitative polymerase chain reaction, confirmed by transcription-mediated amplification, and phylogenetically analyzed as subgenomic cDNA sequences. Among all patients, 19 of 1036 (1.8%) who had IgG anti-HEV before transfusion were reexposed; 40 of 2348 (1.7%) without pretransfusion IgG anti-HEV seroconverted. These 59 patients were linked to 257 donations, 1 of which was positive by reverse-transcription quantitative polymerase chain reaction and transcription-mediated amplification. Plasma from this donation contained 5.5 log IU/mL of HEV RNA that grouped with HEV genotype 3, clade 3abchij. The patient-recipient of RBCs from this donation had a greater than eightfold IgG increase; however, clinical data are unavailable. This is the first report of probable HEV transmission via transfusion in the United States, although it has been frequently observed in Europe and Japan. Additional data on the magnitude of the risk in the United States are needed.
Sections du résumé
BACKGROUND
Hepatitis E virus (HEV) can inapparently infect blood donors. To assess transfusion transmission of HEV in the United States, which has not been documented, a donor-recipient repository was evaluated.
STUDY DESIGN AND METHODS
To identify donations that contained HEV RNA and were linked to patient-recipients with antibody evidence of HEV exposure, we assayed samples from the Retrovirus Epidemiology Donor Study (REDS) Allogeneic Donor and Recipient repository that represents 13,201 linked donations and 3384 transfused patients. Posttransfusion samples, determined to contain IgG anti-HEV by enzyme-linked immunosorbent assay, were reassayed along with corresponding pretransfusion samples for seroconversion (incident exposure) or at least fourfold IgG anti-HEV increase (reexposure). HEV-exposed patients were linked to donations in which HEV RNA was then detected by reverse-transcription quantitative polymerase chain reaction, confirmed by transcription-mediated amplification, and phylogenetically analyzed as subgenomic cDNA sequences.
RESULTS
Among all patients, 19 of 1036 (1.8%) who had IgG anti-HEV before transfusion were reexposed; 40 of 2348 (1.7%) without pretransfusion IgG anti-HEV seroconverted. These 59 patients were linked to 257 donations, 1 of which was positive by reverse-transcription quantitative polymerase chain reaction and transcription-mediated amplification. Plasma from this donation contained 5.5 log IU/mL of HEV RNA that grouped with HEV genotype 3, clade 3abchij. The patient-recipient of RBCs from this donation had a greater than eightfold IgG increase; however, clinical data are unavailable.
CONCLUSIONS
This is the first report of probable HEV transmission via transfusion in the United States, although it has been frequently observed in Europe and Japan. Additional data on the magnitude of the risk in the United States are needed.
Identifiants
pubmed: 30702157
doi: 10.1111/trf.15140
pmc: PMC6501795
mid: NIHMS1005257
doi:
Substances chimiques
RNA, Viral
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
1024-1034Subventions
Organisme : NIOSH CDC HHS
ID : K01 OH010193
Pays : United States
Organisme : NIEHS NIH HHS
ID : R01 ES026973
Pays : United States
Organisme : NHLBI NIH HHS
ID : R21 HL121740
Pays : United States
Informations de copyright
© 2019 AABB.
Références
Open Forum Infect Dis. 2016 Jan 18;3(1):ofw006
pubmed: 27014710
Emerg Infect Dis. 2007 Apr;13(4):648-9
pubmed: 17561564
Euro Surveill. 2014 May 29;19(21):
pubmed: 24906377
Nucleic Acids Res. 2008 Jul 1;36(Web Server issue):W465-9
pubmed: 18424797
N Engl J Med. 2012 Sep 27;367(13):1237-44
pubmed: 23013075
Transfusion. 2004 Jun;44(6):934-40
pubmed: 15157263
J Clin Microbiol. 2002 Jan;40(1):117-22
pubmed: 11773103
J Med Virol. 2017 Jun;89(6):1055-1061
pubmed: 27922197
Transfusion. 2016 Oct;56(10):2532-2537
pubmed: 27453197
Transfusion. 2005 Jul;45(7):1073-83
pubmed: 15987350
Transfusion. 2014 Nov;54(11):2833-41
pubmed: 24797372
Transfusion. 2017 Feb;57(2):267-272
pubmed: 28194857
J Med Virol. 2004 Dec;74(4):563-72
pubmed: 15484278
Transfusion. 2008 Jul;48(7):1368-75
pubmed: 18651907
Vox Sang. 2015 Nov;109(4):406-9
pubmed: 26031310
J Clin Microbiol. 2011 Dec;49(12):4164-72
pubmed: 21998412
Euro Surveill. 2013 Aug 01;18(31):
pubmed: 23929229
J Gen Virol. 2016 Mar;97(3):537-542
pubmed: 26743685
J Gen Virol. 1999 Jan;80 ( Pt 1):169-177
pubmed: 9934699
J Infect Dis. 2015 Feb 1;211(3):366-73
pubmed: 25147277
J Infect Dis. 1993 Aug;168(2):369-78
pubmed: 8335973
J Hepatol. 2012 Dec;57(6):1374-8
pubmed: 22885386
Emerg Infect Dis. 2012 Aug;18(8):1274-81
pubmed: 22840216
Transfusion. 2013 Oct;53(10 Pt 2):2505-11
pubmed: 23829163
Transfusion. 2018 May;58(5):1254-1263
pubmed: 29520800
J Infect Dis. 2009 Jul 1;200(1):48-56
pubmed: 19473098
Lancet. 2000 Sep 23;356(9235):1081-2
pubmed: 11009149
Sci Total Environ. 2015 Feb 1;505:487-93
pubmed: 25461050
Euro Surveill. 2017 Apr 20;22(16):
pubmed: 28449730
Hepatology. 2012 Apr;55(4):988-97
pubmed: 22121109
Lancet. 2014 Nov 15;384(9956):1766-73
pubmed: 25078306
Transfusion. 2017 Dec;57(12):2958-2964
pubmed: 28833188
Transfus Med. 2017 Apr;27(2):84-95
pubmed: 28382704
Transfusion. 2016 Nov;56(11):2781-2789
pubmed: 27557553
Transfusion. 2017 Feb;57(2):280-288
pubmed: 28144952
Virol J. 2010 Sep 06;7:213
pubmed: 20815928
Liver Int. 2016 Apr;36(4):467-72
pubmed: 27005692
J Gen Virol. 2015 Nov;96(11):3255-3264
pubmed: 26282123
Virology. 1992 Dec;191(2):550-8
pubmed: 1448913
Virus Res. 2006 Sep;120(1-2):57-69
pubmed: 16472882
J Clin Microbiol. 2011 Apr;49(4):1234-9
pubmed: 21307208
J Virol Methods. 2006 Jan;131(1):65-71
pubmed: 16125257
Viruses. 2015 May 22;7(5):2704-26
pubmed: 26008708
J Infect Dis. 1992 May;165(5):835-45
pubmed: 1569334
J Clin Virol. 2007 Aug;39(4):318-21
pubmed: 17604686
Hepatology. 2015 Apr;61(4):1441-2
pubmed: 24995930
Emerg Infect Dis. 2017 Jul;23(7):1191-1193
pubmed: 28628452
Transfusion. 2017 Feb;57(2):273-279
pubmed: 28194856
Transfusion. 2017 Feb;57(2):258-266
pubmed: 28144956
Transfus Med. 2006 Apr;16(2):79-83
pubmed: 16623913
Nucleic Acids Res. 1994 Nov 11;22(22):4673-80
pubmed: 7984417
J Clin Microbiol. 2017 May;55(5):1478-1487
pubmed: 28228493
Vox Sang. 2016 Jan;110(1):93-130
pubmed: 26198159
Syst Biol. 2010 May;59(3):307-21
pubmed: 20525638
J Infect Dis. 1995 Oct;172(4):927-33
pubmed: 7561211
Transfusion. 2016 Feb;56(2):481-8
pubmed: 26434952
Genome Announc. 2017 Feb 16;5(7):
pubmed: 28209837